Based on the results of our study, we conclude that
intravenously administered dose of 20mg HBB was effective in
significantly decreasing the duration of the first stage of labor
only in multigravida women, and not associated with any
obvious adverse outcomes on mothers and neonates. However,
more research with a prospective study design and a larger
sample size is needed to establish the exact dose and definite
outcome for using HBB during management of normal labor